Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Yoav Lurie

Randomized Trial of Peginterferon Alfa-2b and Ribavirin for 48 or 72 Weeks in Patients With Hepatitis C Virus Genotype 1 and Slow Virologic Response

Hepatology

Medicine

Hepatology

2010

English

An Unusual Case of Signet Ring Cell Cholangiocarcinoma- Case Report and a Review of Literature

Advanced Research in Gastroenterology & Hepatology

2017

English

Related publications

Peginterferon Alfa-2b and Ribavirin Therapy in Kuwaiti Patients With Chronic Hepatitis C Virus Infection

Eastern Mediterranean Health Journal

Medicine

2011

English

Telaprevir Is Effective Given Every 8 or 12 Hours With Ribavirin and Peginterferon Alfa-2a or -2b to Patients With Chronic Hepatitis C

English

A Randomized Trial of 24 Versus 48 Weeks of Peginterferon Α-2a in Patients Infected With Chronic Hepatitis C Virus Genotype 2 or Low Viral Load Genotype 1: A Multicenter National Study in Japan

Hepatology International

Hepatology

2009

English

A Randomized, Controlled Study of Peginterferon Lambda-1a/Ribavirin ± Daclatasvir for Hepatitis C Virus Genotype 2 or 3

SpringerPlus

Multidisciplinary

2016

English

PGI18 Treatment of Chronic Hepatitis C Patients With Peginterferon Alfa-2a or Peginterferon Alfa-2b: A Cost-Effectiveness Analysis for the Portuguese NHS Setting

English

Efficacy of Boceprevir, an NS3 Protease Inhibitor, in Combination With Peginterferon Alfa-2b and Ribavirin in Treatment-Naive Patients With Genotype 1 Hepatitis C Infection (SPRINT-1): An Open-Label, Randomised, Multicentre Phase 2 Trial

The Lancet

Medicine

2010

English

Optimum Ribavirin Exposure Overcomes Racial Disparity in Efficacy of Peginterferon and Ribavirin Treatment for Hepatitis C Genotype 1

American Journal of Gastroenterology

Hepatology

Gastroenterology

2012

English

Renal Dysfunction With Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin Therapy

Acta Hepatologica Japonica

Hepatology

2012

English

Sustained Virologic Response and IL28B Single-Nucleotide Polymorphisms in Patients With Chronic Hepatitis C Treated With Pegylated Interferon Alfa and Ribavirin.

Acta Biochimica Polonica

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Yoav Lurie

Randomized Trial of Peginterferon Alfa-2b and Ribavirin for 48 or 72 Weeks in Patients With Hepatitis C Virus Genotype 1 and Slow Virologic Response

An Unusual Case of Signet Ring Cell Cholangiocarcinoma- Case Report and a Review of Literature

Related publications

Peginterferon Alfa-2b and Ribavirin Therapy in Kuwaiti Patients With Chronic Hepatitis C Virus Infection

Telaprevir Is Effective Given Every 8 or 12 Hours With Ribavirin and Peginterferon Alfa-2a or -2b to Patients With Chronic Hepatitis C

A Randomized Trial of 24 Versus 48 Weeks of Peginterferon Α-2a in Patients Infected With Chronic Hepatitis C Virus Genotype 2 or Low Viral Load Genotype 1: A Multicenter National Study in Japan

A Randomized, Controlled Study of Peginterferon Lambda-1a/Ribavirin ± Daclatasvir for Hepatitis C Virus Genotype 2 or 3

PGI18 Treatment of Chronic Hepatitis C Patients With Peginterferon Alfa-2a or Peginterferon Alfa-2b: A Cost-Effectiveness Analysis for the Portuguese NHS Setting

Efficacy of Boceprevir, an NS3 Protease Inhibitor, in Combination With Peginterferon Alfa-2b and Ribavirin in Treatment-Naive Patients With Genotype 1 Hepatitis C Infection (SPRINT-1): An Open-Label, Randomised, Multicentre Phase 2 Trial

Optimum Ribavirin Exposure Overcomes Racial Disparity in Efficacy of Peginterferon and Ribavirin Treatment for Hepatitis C Genotype 1

Renal Dysfunction With Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin Therapy

Sustained Virologic Response and IL28B Single-Nucleotide Polymorphisms in Patients With Chronic Hepatitis C Treated With Pegylated Interferon Alfa and Ribavirin.